LSD-Based Med for Anxiety Receives FDA Breakthrough Status LSD-Based Med for Anxiety Receives FDA Breakthrough Status

A single oral dose of lysergide d-tartrate (MM-120) led to clinically and statistically significant reduction in generalized anxiety disorder through 12 weeks.Medscape Medical News
Source: Medscape Psychiatry Headlines - Category: Psychiatry Tags: Psychiatry Source Type: news